临床试验

Study of Sonodynamic Therapy in Participants With Recurrent High-Grade Glioma

NCT：NCT04559685 · TERMINATED

NCT编号NCT04559685

状态TERMINATED

开始日期2021-03-15

完成时间2024-11-10

SponsorNader Sanai (OTHER)

First posted2020-09-23

Last updated2026-05-14

简要摘要

A Phase 0 single center, first in human, open-label study of ascending energy doses of sonodynamic therapy (SDT) utilizing the MRgFUS combined with intravenous ALA to assess safety and efficacy in up to 45 participants with recurrent HGG. Eligible participants who are scheduled for resection will be administered intravenous (IV) aminolevulinic acid HCl (ALA) approximately six to seven (6-7) hours prior to receiving sonodynamic therapy (SDT).

官方来源

在 ClinicalTrials.gov 上查看 →

数据来自 ClinicalTrials.gov API。有关最新状态，请参阅官方记录。